Q-omics provides the consensus-scored LHX8 profile across patient tissues and cancer cell-line models. LHX8 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LHX8 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LHX8 RNA expression shows 6,801 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, KIRC, and STAD as cancer lineages where LHX8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LHX8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LHX8 survival associations across molecular data types. LHX8 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LHX8 RNA expression–survival associations across cancer types. High LHX8 expression shows unfavorable associations in BLCA, KIRP, SARC, READ and UCEC, but favorable associations in LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for LHX8 RNA expression.
This table summarizes LHX8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LHX8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LHX8 shows lower tumor expression in BLCA and THCA and higher tumor expression in KIRC, LUSC, LUAD and KIRP. The KIRC box plot shows higher LHX8 RNA expression in tumor versus normal tissue (log2 FC = +0.507, t-test p < 0.001).
This table shows molecular features associated with LHX8 in patient tissues and cancer cell lines. In patient samples, LHX8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LHX8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
